Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn’s Disease

Rutgeerts, P. (1998). The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease. Mediators of Inflammation, 1998(), 137-140. https://doi.org/10.1080/09629359891036
Hashemi, M., Saadat, M., Behjati, M., & Kelishadi, R. (2012). Comparison of Serum Apolipoprotein Levels of Diabetic Children and Healthy Children with or without Diabetic Parents. Cholesterol, 2012(), 47-50. https://doi.org/10.1155/2012/490381
陳西蕙、謝永宏（2022）。Effectiveness and Safety of Biological Therapeutic for Moderate to Severe Crohn's Disease。臺灣臨床藥學雜誌，30(2)，117-128。https://doi.org/10.6168/FJCP.202204_30(2).0003
Kim, H. K., Jang, E. C., Yeom, J. O., Kim, S. Y., Cho, H., Kim, S. S., Chae, H. S., & Cho, Y. S. (2013). Serum Prohepcidin Levels Are Lower in Patients with Atrophic Gastritis. Gastroenterology Research and Practice, 2013(), 124-129-018. https://doi.org/10.1155/2013/201810
Celikbilek, A., Celikbilek, M., Sabah, S., TanJk, N., Borekci, E., Dogan, S., Akin, Y., Baldane, S., Deniz, K., Yilmaz, N., Ozbakir, O., & Yucesoy, M. (2014). The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis. International Journal of Inflammation, (2014), 238-243. https://doi.org/10.1155/2014/986525